BioCentury
ARTICLE | Clinical News

Exviera dasabuvir: Phase IIIb data

August 17, 2015 7:00 AM UTC

The open-label, international Phase IIIb TURQUOISE-III trial in 60 patients with chronic HCV genotype 1b infection with compensated liver cirrhosis showed that Viekirax ombitasvir/paritaprevir/ritonavir plus Exviera dasabuvir without ribavirin for 12 weeks led to an SVR 12 weeks after the end of treatment, the primary endpoint, in 100% of patients. No patients experienced virologic failure during treatment and no patients experienced virologic relapse following the end of treatment. Data were presented at the International Symposium on Viral Hepatitis and Liver Diseases in Berlin. ...